ArticleCancer medicine2020
Urachal carcinoma: Impact of recurrence pattern and lymphadenectomy on long-term outcomes.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Urachal Carcinomas: A Comprehensive Systematic Review and Meta-analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Web-Based Prediction Models for Overall Survival and Cancer-Specific Survival of Patients With Primary Urachal Carcinoma: A Study Based on SEER Database.Frontiers in public health · 2022Trial
- Urachal Carcinoma with Divergent Glandular Enteric-Type and Squamous Differentiation Associated with Bladder Exstrophy: Case Report of an Extremely Rare Entity.Reports (MDPI) · 2026Article
- Robot‑assisted laparoscopic partial cystectomy for urachal carcinoma: A case report.Oncology letters · 2025Article
- A case-based review of urachal carcinoma with mixed small cell neuroendocrine and adenocarcinoma components, with one new case report and analysis of nine published cases.Frontiers in endocrinology · 2025Review
- Urachal adenocarcinoma with cervical invasion misdiagnosed as primary cervical adenocarcinoma: a case report and literature review.Frontiers in oncology · 2024Article
- TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer: Stage-Matched Analysis of a Large Multicenter National Cohort.Cancer research and treatment · 2023Article
- Preoperative accuracy of diagnostic evaluation of urachal carcinoma.Cancer medicine · 2023Article
- Primary urachal leiomyosarcoma: a case report and literature review of clinical, pathological, and medical imaging features.Frontiers in oncology · 2023Article
- Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group.Frontiers in oncology · 2023Article
- Current Management of Urachal Carcinoma: An Evidence-based Guide for Clinical Practice.European urology open science · 2022Review
- Clinical, Pathological, and Prognostic Analysis of Urachal Carcinoma.Urologia internationalis · 2022Article
- Clinical and Radiological Features of Urachal Carcinoma and Infection.Frontiers in oncology · 2021Article
- The Prognosis and Oncological Predictor of Urachal Carcinoma of the Bladder: A Large Scale Multicenter Cohort Study Analyzed 203 Patients With Long Term Follow-Up.Frontiers in oncology · 2021Article
- Construction and Validation of Novel Prediction Tools Based on Large Population-Based Database to Predict the Prognosis of Urachal Cancer After Surgery.Frontiers in oncology · 2021Article
- Urachal Carcinoma: Are Lymphadenectomy and Umbilectomy Necessary?Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Urachal carcinoma: Impact of recurrence pattern and lymphadenectomy on long-term outcomes.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrachal carcinoma is a rare nonurothelial malignant tumor with high rates of local recurrence and systemic metastasis. Although radical resection is widely considered the standard treatment, there is still a debate regarding the benefits of lymphadenectomy. To explore these factors, we investigated the recurrence pattern of urachal cancer and the impact of lymphadenectomy on long-term survival.
methodsThe data of 62 patients pathologically diagnosed with urachal carcinoma at Sun Yat-sen University Cancer Center from 2002 to 2019 were retrospectively reviewed. Lymphadenectomy was defined as lymph nodes retrieved from the obturator, internal iliac, and external iliac lymph node stations. The Kaplan-Meier method and Cox regression model were used to identify prognostic factors. OS and DFS were the primary endpoints.
resultsOf the 47 males and 15 females included, 54 patients underwent partial cystectomy, and 27 patients underwent lymphadenectomy. The number of patients with Sheldon stage IIIA, IIIB, IIIC, IVA, and IVB were 43 (69.4%), 4 (6.5%) 3 (4.8%), 6 (9.7%), and 6 (9.7%), respectively. The median DFS was 32.7 months, and the mean OS was 114.6 months. Sheldon stage (P < .001) and tumor size (P = .001) were identified as independent prognostic factors for DFS, whereas Sheldon stage (P = .003), peritoneal metastasis (P = .006), distant metastasis (P = .024), and recurrence in pelvic lymph nodes (P = .015) were independent prognostic factors for OS.
conclusionsUrachal carcinoma has a high recurrence rate, but only peritoneal metastasis, distant metastasis, and recurrence in pelvic lymph nodes were found to be associated with OS. Lymphadenectomy was recommended because of its role in accurately staging the disease, and further research is needed to focus on lymphadenectomy and standardized the procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.